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Remarkably elevated levels of phospholipase A2 (PLA2)
are measurable in human blood samples in cases of
acute pancreatitis. The source of the enzyme was first
thought to be exclusively the pancreas, but now it is
generally accepted that two isoenzymes − the pancre-
atic PLA2, group I, and the extrapancreatic PLA2, group
II − contribute to the raised activity. In contrast to the
group II-PLA2, the pancreatic PLA2 is heat-resistant for
1 hour at 60 °C. The catalytically inactive proenzyme of
the pancreatic PLA2 can be activated by trypsin. The
aim of our study was to evaluate the diagnostic value
of PLA2 isoenzyme activity measurements to identify
patients with severe complications in acute pancreati-
tis. Blood samples from patients suffering from acute
pancreatitis were analyzed for catalytically active pan-
creatic PLA2 on day 1 and 2 of hospitalization with a
modified radiometric Escherichia coli-based PLA2 as-
say. In 10 of 41 patients clearly elevated values of cat-
alytically active, heat-resistant pancreatic PLA2 (7.2 to
81.2 U/l) were observed. This group of patients was
characterized by severe complications (necrotizing
pancreatitis, shock, sepsis, respiratory problems) of
which two patients subsequently died. Patients with
low or undetectable activity (<7 U/l) of pancreatic PLA2
recovered rapidly. According to these results the pres-
ence of catalytically active pancreatic PLA2 in serum is
associated with severe complications of acute pancre-
atitis. In contrast to total serum-PLA2, the catalytic
concentration of pancreatic PLA2 can serve as a prog-
nostic marker in acute pancreatitis. Clin Chem Lab
Med 2002; 40(3):293–297
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Introduction
The value of serum-phospholipase A2 (PLA2) activity in
acute pancreatitis as prognostic and diagnostic marker
is controversial. Until the late 80‘s PLA2 levels in acute
pancreatitis were believed to be exclusively of pancre-
atic origin. The group I-PLA2 concentration determined
with an immunoassay correlated closely with lipase
and amylase (1). Soon it became evident that the
course of total serum PLA2 activity did not correlate
with the kinetics of other pancreatic enzymes but fol-
lowed those of inflammatory indicators like C-reactive
protein (CRP). It was of interest that the serum PLA2 re-
mained high after total pancreatic necrosis, and even
after total pancreatectomy (2). From these observa-
tions it was concluded that two immunologically differ-
ent isoenzymes are responsible for elevated serum
PLA2 levels in cases of acute pancreatitis.
The heat-resistant pancreatic PLA2 (Pa PLA2) group I
which probably occurs only in pancreatic diseases (3).
Pa PLA2 is secreted as a zymogen which means that a
cleavage from an inactive form is necessary to achieve
enzymatic activity. This zymogen for Pa PLA2 is called
prophospholipase A2 (Pro PLA2). It is not inducible by
cytokines.
A group II-PLA2 which is released from blood cells
and probably from the liver, especially during inflam-
mation (4). This enzyme is inducible by proinflamma-
tory cytokines (5). It is not secreted as a zymogen.
Therefore in studies on the measurements of PLA2
activity in acute pancreatitis a differentiation between
the different PLA2 forms is necessary (6). 
Until now it has not been possible to determine
specifically the activity of the pancreatic PLA2 (group I).
Since it plays a very important role in the pathogenesis
of acute pancreatitis, its measurement would provide
helpful information on diagnosis and, above all, prog-
nosis of the disease. We have developed a sensitive as-
say to measure the fraction of catalytically active pan-
creatic PLA2 (Pa PLA2) out of the total serum PLA2. The
present study is, to our knowledge, the first one com-
paring total PLA2, Pa PLA2 and Pro PLA2 activity with
the acute phase reactants CRP and polymorphonuclear
elastase (PMN-elastase).
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Patients and Methods
This study included 41 patients with acute pancreatitis who
were admitted to the Mannheim Department of Surgery at the
University of Heidelberg. Twenty six patients were male and
15 were female. The mean age was 57 years. Twenty one pa-
tients suffered from biliary pancreatitis and 14 from alcoholic
acute pancreatitis. In three cases pancreatic inflammation
followed endoscopic retrograde cholangiopandeatography
(ERCP) and in one case it was caused by excessive hyperlipi-
demia (triglycerides >11.4 mmol/l). In two patients the cause
of pancreatitis remained obscure. On average, patients with
mild disease had 0.3 complications (Table 1), patients with se-
vere pancreatitis had 3.4 complications and patients who died
had on average 3.5 complications. All patients with mild dis-
ease had edematous pancreatitis, whereas severe and lethal
outcomes were predominantly necrotizing pancreatitis. Al-
most all patients of this group had to undergo laparotomy.
This procedure which involves early removal of necrotic pan-
creatic tissue with subsequent drainage of the peripancreatic
space was prefered in our department.
The diagnosis of acute pancreatitis was confirmed by typical
symptoms, elevated amylase level (normal values <32 U/l) and
characteristic changes in ultrasonography and computerized
tomography. Once the diagnosis was established, the follow-
ing laboratory parameters were determined daily: amylase,
PMN-elastase, CRP and serum PLA2. The day of hospitalization
was defined as day 1. The severity of the disease was assessed
by the clinical outcome and the number of complications that
occured (7). Patients were classified into two groups: mild pan-
creatitis, i.e. less than or equal to one complication (n=31) and
severe/lethal pancreatitis, i.e. greater than or equal to two
complications or lethal outcome (n=10, Table 1).
α-Amylase was determined photometrically (Beckman, Mu-
nich, Germany), CRP and PMN-elastase were determined im-
munologically (Merck, Darmstadt, Germany). 
Total serum PLA2 as well as Pa PLA2 and Pro PLA2 were mea-
sured by modifications of the radioactive E.coli-based assay
described recently in detail (5, 8, 9). Instead of TRIS/HCl as re-
action buffer, an acetate buffer (100 mmol/l; pH 6.0) was used
for optimal activity of the pancreatic enzyme. Catalytic con-
centrations of Pa PLA2 were determined as heat-resistant
PLA2. Serum (150 µl) was heated to 60 °C for 1 hour. The Pro
PLA2 concentration was determined as catalytical activity fol-
lowing activation by trypsin (10). After cooling to room tem-
perature, a 50 µl aliquot was drawn, mixed with 505 units (50
µg) of trypsin from bovine pancreas (Sigma, Deisenhofen,
Germany) in 2 µl of redistilled water and incubated at 37 °C for
5 minutes. Thereafter 150 µg of trypsin inhibitor from soy
bean (Sigma) in 2 µl of redistilled water was added, the reac-
tion mixture vortexed and put on ice. Finally, the activity was
measured by the E.coli-based assay. Stopping the reaction
with antitrypsin was neccessary to protect the E.coli mem-
branes from digestion.
To prove that the enzymes measured as Pa PLA2 and Pro
PLA2 were of pancreatic origin we treated samples from 10 pa-
tients with an inhibitory monoclonal antibody specific for hu-
man pancreatic PLA2 (Roche Diagnostics GmbH, Penzberg,
Germany): 25 µl sample was incubated with 25 µl of the mo-
noclonal antibody (0.2 µg/ml) for 15 minutes at 37 °C.
The Mann-Whitney U-test was used for statistical compari-
son of the medians. All p-values are two-tailed. Predictive val-
ues were calculated for several parameters .
Results 
The inhibition of the Pa PLA2 and Pro PLA2 activity by a
monoclonal antibody specific for human pancreatic
PLA2 is shown in Figure 1. The antibody was able to
completely inhibit the activity observed before or pro-
duced by trypsin activation (p=0.002). This confirms
that the pancreas is the source of Pa PLA2 and Pro PLA2.
In the patient group with mild disease both Pa PLA2
and Pro PLA2 were mostly elevated on the first day of
hospitalization but remained rather low (less than 6.8
U/l). Both correlated temporally but not with respect to
the amount of increase (Figure 2). The measurement of
amylase does not allow conclusions about the ex-
pected increase in Pa PLA2 or Pro PLA2 activity. In con-
trast to amylase, particularly the Pa PLA2 activity de-
pends on the severity of the disease. After the second
day Pa PLA2 activity was low or not detectable. In the
sera from patients with severe disease much higher
values of Pa PLA2 were observed (7.2 to 81.2 U/l). Here
too, the maximum was usually reached on the first day
of hospitalization. In this group of patients Pro PLA2
Table 1 Complications of acute pancreatitis in the studied patients.
Mild Severe Lethal All
(n=31) (n=8) (n=2) (n=41)
Pneumonia, atelectasis, pleural effusion 2 8 0 10
Respiratory insufficiency (paO2<60 mmHg) 0 6 1 7
Ascites, retroperitoneal effusion 5 5 0 10
Ileus 0 0 0 0
Diabetes mellitus 0 0 0 0
Consumptive coagulopathy 0 0 0 0
Cholangitis/cholecystitis 1 0 1 2
Renal failure 0 1 1 2
Encephalopathy 0 0 0 0
Pancreatic pseudocyst 1 2 0 3
Cholestasis 0 0 1 1
Upper gastrointestinal bleeding 1 1 0 2
Sepsis 0 2 2 4
Shock 0 2 1 3
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levels were somewhat higher. Further, serum PLA2 ac-
tivity reached its maximum on day 3 and did not show
any correlation with other pancreatic enzymes. 
We investigated five laboratory parameters to define
their potential use for an individual prognosis. They
were determined in samples from each patient on day
1 and 2 of hospitalization, but only the higher of the two
values was used for statistical calculations. Except for
Pa PLA2, all other parameters were not reliable con-
cerning prognosis in individual cases, although they
proved to be of statistical value (Table 2). Figures 3 and
4 show an interesting comparison between total serum
PLA2 and Pa PLA2 with regard to initial assessment of
prognosis. According to the nonparametric U-test,
serum PLA2 was well able to differentiate between mild
and severe/lethal pancreatitis (p=0.0061), but Figure 3
shows clearly that this has no meaning for the individ-
ual patient. For PMN-elastase the situation appears to
be similar (Table 2). Its values differed significantly be-
tween the two groups (p=0.033) but did not allow reli-
able conclusions concerning clinical outcomes. Ac-
cording to this study, the CRP maxima on the first 2
days of hospitalization could not even differentiate be-
tween mild and severe pancreatitis, in contrast to PMN-
elastase (p=0.476). Pro PLA2 values can differentiate
only with marginal significance (p=0.051), and sensitiv-
ity and specificity (0.60 and 0.65, respectively) suggest
that this test is not suitable for clinical use. In contrast,
the situation for Pa PLA2 activity is completely different.
In both groups the values did not even overlap, so that
mild (edematous) and severe (necrotizing) forms of the
disease could be readily distinguished (Table 2, Figure
4). The calculation of the cut-off values for the best di-
agnostic sensitivity and specificity for the total serum
PLA2 activity and the pancreatic PLA2 activity was per-
Figure 1 Inhibition of pancreatic phospholipase A2 by a
monoclonal antibody (MAB) (n=10). a: Activities measured af-
ter heating for 60 minutes (Pa PLA2) and b: after additional in-
cubation with trypsin for 5 minutes (Pro PLA2). c: and d: Activ-
ities after addition of an inhibitory MAB specific for human
pancreatic PLA2. Complete inactivation was observed in all
samples.
Figure 2 Time course of enzyme activities (medians) after
admission to the hospital. Pa PLA2 and Pro PLA2 show obvious
similarity to amylase. In contrast, serum PLA2 does not corre-
late with pancreatic enzymes.
Table 2 The measurement of phospholipases and inflammation statistical data.
Serum- Pa PLA2 Pro PLA2 CRP Elastase
PLA2
Cut-off 100 U/l 7 U/l 15 U/l 300 mg/l 200 µg/l
Sensitivity 60% 100% 60% 40% 60%
Specificity 83.9% 100% 65% 87.1% 74.2%
PPV1 54.5% 100% 37.5% 50% 42.9%
NPV2 86.7% 100% 84% 81.8% 85.2%
p-Value3 0.0061 <0.0001 0.051 0.476 0.033
1positive predictive value; 2negative predictive value; 3differentiation between mild and severe disease
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formed by receiver operating characteristics (ROC)
analysis and discrimination analysis.
Discussion
One of the most important questions concerning acute
pancreatitis is the early differentiation between mild
and severe forms of the disease. Laboratory tests such
as lipase and amylase and also computerized tomogra-
phy and ultrasonography serve as sufficient means to
diagnose this dangerous disorder. However, the as-
sessment of the individual prognosis by these means
still remains questionable (11).
Although these results must be interpreted with cau-
tion due to the rather small number of patients, the cat-
alytically active pancreatic PLA2 seems to be a good in-
dicator of the pancreatic damage. Acute pancreatitis is
an autodigestive disease in which digestive enzymes
synthesized in the pancreatic acinar cells destroy the
gland. Schmidt and Creutzfeldt came to the conclusion
that pancreatic PLA2 might be responsible for the glan-
dular and periglandular tissue necrosis (12, 13). These
findings have been confirmed by others (14, 15). It can
be assumed that elevated activities of Pa PLA2 in serum
reflect necrotizing processes in the pancreas itself as
well as extrapancreatic organ failures such as pul-
monary or renal complications initiated by this en-
zyme. This is supported by the finding that Pa PLA2 ac-
tivity is detectable in peritoneal effusion and pleural
fluid during acute pancreatitis (16, 17). From there, the
Pa PLA2-enriched fluids diffuse to pulmonary struc-
tures with subsequent destruction of the lungs. Fur-
thermore, intraperitoneal Pa PLA2 leads to enhanced
translocation of bacteria through the intestinal wall
into the mesenteric lymph nodes with subsequent bac-
teremia (18). Additionally, Pa PLA2 causes a marked de-
crease in the pancreatic blood flow and damage to in-
tra-abdominal nerve plexus followed by the inhibition
of intestinal motility (19).
Interestingly, total PLA2 serum activity kept increas-
ing until day 3 despite decreasing Pa PLA2 and Pro PLA2
activities. This is due to increasing PLA2-II activity. It is
suggested that this enzyme may also be responsible
for multiorgan failure in acute pancreatitis because this
is the key enzyme for the eicosanoid mediator synthe-
sis. Therefore PLA2-II inhibitors were developed and
tested (20, 21). This early increase in Pa PLA2 followed
by an increase in PLA2-II could also be demonstrated in
cerulein-induced acute pancreatits in rats (22).  Further-
more, our CRP measurements are consistent with the
previous studies of other authors (23) and of our group
which demonstrated that CRP is not a useful tool to dis-
tinguish between mild and severe forms of acute pan-
creatitis (24).
In conclusion, we demonstrated that Pa PLA2 activity
in serum is strongly elevated in severe acute pancreati-
tis and that it allows a discrimination between mild and
severe forms of this disease in its early phase. As this
enzyme may at least in part contribute to multiorgan
failure, we suggest that it is worthwhile to develop and
test specific inhibitors of Pa PLA2 or proteinase in-
hibitors which would inhibit the cleavage of the active
enzyme from Pro PLA2. 
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